A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug interactions between necitumumab and gemcitabine-cisplatin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Antibodies, Monoclonal; Cisplatin; Gemcitabine; Necitumumab

Criteria

Inclusion Criteria:

• Have documented advanced or metastatic malignant solid tumors (except for colorectal tumors with KRAS mutation) that are resistant to standard therapy or for which no standard therapy is available

• May have measurable or non-measurable disease

• Have resolution to Grade 0 or 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE 4.0) of all clinically significant toxic effects (other than alopecia) of prior chemotherapy, surgery, radiotherapy, or hormonal therapy

• Have an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1

• Have adequate hepatic, hematologic and renal function

• If female, are surgically sterile, postmenopausal, or agree to be compliant with a highly effective contraceptive method during and for 6 months after the treatment period. If male, are surgically sterile or agree to be compliant with a highly effective contraceptive regimen during and for 6 months after the treatment period

• Female participants of childbearing potential have a negative serum pregnancy test within 7 days prior to the first dose of study therapy

Exclusion Criteria:

• Have received a systemic anticancer agent (including EGFR tyrosine kinase inhibitors) or device within 28 days prior to first dose of study therapy

• The most recent anticancer therapy received by the participant included either gemcitabine or cisplatin (or both)

• Have received radiotherapy within 14 days prior to first dose of study therapy

• Have received cytotoxic chemotherapy within 21 days prior to first dose of study therapy

• Are receiving concurrent treatment with another anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiation therapy, chemoembolization, or targeted therapy

• Are considered surgical candidates (with resectable disease)

• Have brain metastases that are symptomatic or require ongoing treatment with steroids or anticonvulsants

• Have narrowing of or blockage in large veins

• Have coronary artery disease or uncontrolled congestive heart failure

• Have uncontrolled angina pectoris, or experienced myocardial infarction within 6 months prior to first dose of study therapy

• Have an ongoing or active infection (requiring treatment), including active tuberculosis or known infection with the human immunodeficiency virus

• Have a history of significant neurological or psychiatric disorders, including dementia, seizures, or bipolar disorder

• Have known drug or alcohol abuse

• If female, are pregnant or breastfeeding

• Have had major surgery within 28 days prior to first dose of study medication or subcutaneous venous access device implantation within 7 days prior to first dose of study therapy

• Are currently enrolled in, or discontinued within the 30 days prior to first dose of study therapy from a clinical trial involving an investigational product or nonapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study